Clinical trials: Acute-Phase Response
Core Binding Factor Acute Myeloid Leukemia
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute…
- Trial name
- NCT06917911
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Cytarabine
- Where
- 74 sites in United States, Puerto Rico
- Volunteers
- 162 people
- Sponsor
- National Cancer Institute (NCI)
Sepsis and Septic Shock, Acute Respiratory Failure
Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
Kidney transplantation is the treatment of choice for end-stage chronic kidney disease. Kidney transplantation is at the first rank of solid organ transplantation in France, with 3,376 grafts performed in 2022.
- Conditions
- Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients, Immunosuppressive Agents
- Trial name
- REDIS (NCT06881927)
- Testing
- Hydrocortisone Hemisuccinate: 200 mg per day., reduction of the level of immunosuppression
- Where
- France
- Volunteers
- 212 people
- Sponsor
- University Hospital, Strasbourg, France
Systemic Inflammatory Response Syndrome, Coronary Artery Bypass Grafting
Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)
EA-230 is a newly developed synthetic compound with anti-inflammatory properties, it is a linear tetrapeptide derived from the human chorionic gonadotropin hormone (hCG).
- Trial name
- EASI (NCT03145220)
- Testing
- EA-230
- Where
- Netherlands
- Volunteers
- 180 people
- Sponsor
- Radboud University Medical Center
Acute Myeloid Leukemia
CNDO-109-AANK for AML in First Complete Remission (CR1)
This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a…
- Trial name
- NCT01520558
- Testing
- CNDO-109-AANK Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Coronado Biosciences, Inc.
Leukemia
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to compare how well 2 different dosing schedules of decitabine may help control AML.
- Trial name
- NCT01786343
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Toxic Effects, Tumor Responses
Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial
Nasopharyngeal carcinoma (NPC) is a common malignant tumor in Southern China area, which is characterized by obvious regional characteristics and "Guangdong cancer".
- Trial name
- NCT03188497
- Testing
- Lobaplatin, linear accelerator
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Critically Ill, Acute Kidney Injury
Non-interventional Follow-up Versus Fluid Bolus in RESPONSE to Oliguria in the Critically Ill
Background: After hypotension, oliguria (urine output less than 0.5 mL/kg/h) was the most common trigger to administer fluid bolus in a multinational practice survey in intensive care.
- Conditions
- Critically Ill, Acute Kidney Injury, Sepsis, Oliguria
- Trial name
- RESPONSE (NCT02860572)
- Testing
- follow-up without intervention, fluid bolus
- Where
- 2 sites in Finland
- Volunteers
- 130 people
- Sponsor
- Helsinki University Central Hospital
Septic Shock, Acute Renal Failure (as Defined by the "Failure" Stage of the RIFLE Classification)
I.D.E.A.L.-I.C.U. (Initiation of Dialysis EArly Versus deLayed in Intensive Care Unit)
The purpose of this multicentric, randomized controlled trial is to assess whether the timing of renal replacement therapy initiation (early vs delayed) has an impact on mortality at 90 days in patients with severe acute kidney…
- Trial name
- IDEAL-ICU (NCT01682590)
- Testing
- Renal Remplacement Therapy
- Where
- 27 sites in France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Laparotomy, Laparoscopy
Remote Ischemic Conditioning in Abdominal Surgery
This phase II randomized (1:1) controlled trial will examine the effects of remote ischemic conditioning (RIC) on the outcomes of major abdominal surgery.
- Conditions
- Laparotomy, Laparoscopy, Retroperitoneal Disease, Pelvis Disease
- Trial name
- NCT03234543
- Testing
- Remote ischemic conditioning, No Remote ischemic conditioning
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Rutgers, The State University of New Jersey
Healthy Women Giving Birth to Singleton Infants
Making Maternal Post-partum Vitamin A Supplementation Effective: The Role of Timing and Inflammation
Background: Vitamin A is of utmost importance for health and survival of children. A recent series in The Lancet on maternal and child health put vitamin A deficiency at the top of most important micronutrient deficiencies…
- Trial name
- NCT00952640
- Testing
- vitamin A
- Where
- Vietnam
- Volunteers
- 400 people
- Sponsor
- Institut de Recherche pour le Developpement
Acute Kidney Injury Due to Sepsis
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)
The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting…
- Trial name
- CLEAR-AKI (NCT05996835)
- Testing
- TIN816 70 mg lyophilisate powder
- Where
- 79 sites in United States, Argentina and 15 more
- Volunteers
- 316 people
- Sponsor
- Novartis Pharmaceuticals
Sepsis, Community-acquired Pneumonia
A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
- Conditions
- Sepsis, Community-acquired Pneumonia, Urinary Tract Infections, Cholecystitis, Acute
- Trial name
- NCT04612413
- Testing
- Allocetra-OTS
- Where
- 31 sites in Belgium, France and 3 more
- Volunteers
- 148 people
- Sponsor
- Enlivex Therapeutics Ltd.
Surgery, Postoperative Complications
Carbohydrates and Proteins 3h Before Surgery
Prolonged pre-operative fasting increases postoperative hospital stay and current evidence recommends carbohydrate (CHO) drinks 2 hours before surgery.
- Conditions
- Surgery, Postoperative Complications, Inflammation
- Trial name
- NCT01563965
- Testing
- Carbohydrate plus hydrolyzed protein beverage, Preoperative fasting of 8h
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Federal University of Mato Grosso
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
Covid19, SARS-CoV Infection
RECOVAC - Long Term Efficacy and Safety of COVID-19 (SARS-CoV-2) Vaccination in Kidney Disease Patients
Rationale: COVID-19 is associated with severely increased morbidity and mortality in patients with chronic kidney disease stage G4-G5 and patients on dialysis or after kidney transplantation.
- Conditions
- Covid19, SARS-CoV Infection, Chronic Kidney Diseases
- Trial name
- LESS CoV-2 (NCT04841785)
- Testing
- mailer-based finger-prick
- Where
- Netherlands
- Volunteers
- 4,868 people
- Sponsor
- University Medical Center Groningen
Migraine, Thrombophilia
Acute Phase Reactions and Thrombophilia in Pediatric Patients With Migraine
Acute Migraine attacks can be related to vascular or coagulation activation. Previous studies found relative high incidence of prothrombotic events in Migraine.
- Trial name
- NCT01905748
- Testing
- Laboratory tests
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- HaEmek Medical Center, Israel
Schizophrenia
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.
- Trial name
- NCT00580125
- Testing
- PF-00217830, Aripiprazole
- Where
- 26 sites in United States, India and 2 more
- Volunteers
- 164 people
- Sponsor
- Pfizer
Ketosis, Acute-Phase Response
Metabolic Effects of Whey Protein Supplementation After Fasting in Volunteers
This study aims to investigate the early metabolic effects and acute phase response of an oral clear supplement containing whey protein plus carbohydrates in young healthy volunteers during fasting-induced organic response
- Conditions
- Ketosis, Acute-Phase Response, Insulin Resistance
- Trial name
- NCT05656339
- Testing
- CHO+WP, CHO, Fast
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Federal University of Mato Grosso
Acute Myeloid Leukemia
Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission
The primary aim of this innovative immunotherapeutic study is to determine whether the antileukemic effects seen in our previous phase I/II study can be confirmed in a large cohort of patients and whether dendritic cell…
- Trial name
- WIDEA (NCT01686334)
- Testing
- DC vaccine
- Where
- 8 sites in Belgium
- Volunteers
- 130 people
- Sponsor
- Zwi Berneman
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.